Managing failure to antiretroviral therapies implies the addressing of several issues: the clinical stage, the virological and the immunological response to the failing regimen, together with drug history, resistance and exposure. Each of these issues will be discussed with the aim of providing useful data to design an optimal antiretroviral rescue therapy.
WHAT IS FAILURE? An association between plasma viral load (pVL) and progression to AIDS is well established (1). Further, the decrease in AIDS related deaths and in the number of opportunistic infections that have been observed in recent years have been attributed to viral suppression achieved with the use of highly activeantiretroviral therapy (HAART) (2) . Achieving pVL values of less than 50 copies/mL has been proved to be the best predictor oflong term virological response (3) . However, less than 50% of HIVinfected individuals receiving HAART achieve a durable suppression of viral replication (4, 5) and about 30% of HIV -infected subjects receiving HAART exhibit a sustained CD4+ T-Iymphocyte response despite incomplete virological response (6) (7) . Several mechanisms have been proposed to account for such paradoxical immune responses, including the prevention of T cell apoptosis by protease inhibitors (PIs) (8) (9) , an alteration in T cell turnover kinetics (10) , and changes in viral fitness associated with acquired resistance mutations to PIs (11-13). On the other hand, patients may have persistently low CD4+ cell counts despite a significant decrease in pVL (7) . Several investigators studied the effect of virological rebound on CD4+ cell counts and on HIV -related events among patients treated with HAART (14) (15) (16) (17) . In 497 HIV-infected subjects, Bahrani and colI. (16) found that the CD4+ response to HAART at 24 months was not statistically different between those who reached undetectable pVL (HIV-RNA less than 400 copies/ mL) and those who reached HIV-RNA values between 400 and 10,000 copies/mL. On the contrary, patients whose pVL did not fall below 10,000 copies/mL had a significant decrease in their CD4+ cell counts over 24 months. An inverse correlation between CD4 cell counts and the magnitude of viral rebound was also observed. Piketty and colI. (17) observed that in 150 patients with a mean of72 baseline CD4+ Tvlymphocytes/ul., the incidence of AIDS defining events and deaths (14%) at 30 months among those with immunologic responses in the absence of a virologic response was higher than that in full-responders (2%). Yet, the incidence in this group was lower than that among patients with no immunologic response, despite virologic response (21 %), and was lower than that in subjects without either an immunologic or a virologic response (67%).
However, as HIV-1 mutations accumulate during viral evolution, drug resistance is frequently selected when viral replication is not fully suppressed. Furthermore, the longer a patient remains on a submaximally suppressive drug regimen, the greater is the likelihood of subsequent cross-resistance and failure using drugs within the same class (18) (19) .
Thus, the choice of the most appropriate time point to change a submaximally suppressive regimen should take into account the following issues: 1) the goal of achieving pVL levels below the limit of detection (hopefully below the limit of 50 copies/mL) should be pursued at least with the first or the second HAART regimen; 2) unfortunately, in drug-experienced HIV -1 infected persons this goal is often unreachable even when antiretroviral treatment changes are guided by the results of a resistance test, with or without expert advise (20) (21) (22) ; 3) a low level HIV-l replication might be an acceptable result after more than one virological failure, provided that a good immunological response has been achieved.
CAUSES OF DRUG FAILURE
The main causes offailure to a HAART regimen are inadequate drug exposure (24) and the presence of previous resistance to antiretrovirals (25) . Drug .exposure may be assessed by the evaluation of non-nucleoside reverse transcriptase inhibitors (NNRTIs) or of PIs plasma concentrations. However, which pharmacokinetic parameter(s) (C . ,C 1 h' AUC) is (are) to be taken into account min roug to evaluate this issue is not yet defined. Moreover, although therapeutic drug monitoring at the time of virological breakthrough may be useful to assess the cause of failure to NNRTIs or PIs, it is not helpful for nucleoside reverse transcriptase inhibitors (NRTIs). In fact, the establishment of a relationship between NRTIs plasma concentrations and antiviral effect has been elusive because measurement of the active moiety, the intracellular triphosphate, is analytically challenging. Furthermore, therapeutic drug monitoring at the time of failure does not allow avoiding the development of drug resistance. As discussed below, resistance test at the time of drug failure may help to design a more effective salvage regimen.
CONSEQUENCES OF DRUG RESISTANCE
Resistance to antiretroviral drugs has been related to virologic failure, immunologic failure, and disease progression (18, (26) (27) . However, in the presence of HIV-1 variants bearing mutations associated to resistance to PIs or the 184V substitution, selected by treatment with lamivudine, viral replication may be impaired (i.e. viral fitness may be reduced), thus attenuating the unfavorable impact of the selection of resistance (11-13, [28] [29] . It must be underscored that this effect may vanish after accumulation of multiple secondary mutations (11, 30) . Furthermore, it has been recently demonstrated that cytotoxic T-lymphocytes can specifically recognize lamivudine-resistant HIV-I mutants (31) (32) .
On the other hand, the rapid rebound of variants bearing the 181C or the 103N mutation (selected by either nevirapine or efavirenz) suggests that these single mutations have a limited impact on viral fitness (33) . Indeed, evidence exists that some variants resistant to NNRTIs may have enhanced replication capacity (34) . Therefore, as NNRTIs-related mutations are rapidly and unavoidably selected when HIV-I replication is not fully suppressed, NNRTIs should be discontinued soon after virological failure is confirmed.
A number of mutations selected by certain drugs may have a favorable effect on drug susceptibility to other compounds. For example, the 184V substitution can delay or revert resistance to zidovudine (35) , and the 88S mutation (often selected by nelfinavir) can confer hypersensitivity to amprenavir (36) . Finally, the 181 C substitution has been demonstrated to partially restore sensitivity to zidovudine, when zidovudine-related mutations are present (37), and NNRTI hypersensitivity was observed in 20 to 30% of NRTI-resistant isolates (38) . The clinical implications ofthese observations need to be determined. In particular, it is not clear how long the benefit of a mutation selected by a failing drug persists when the same drug is withdrawn. However, in NNRTI naive patients, salvage regimens including NNRTIs may be more effective compared with those in which this class of drugs has been spared (39-41).
RESISTANCE TO ANTIRETROVIRAL DRUGS
Cross-resistance occurs at a variable extent to each of the three available classes of antiretroviral drugs. For this reason, a wise drug sequencing within each class seems to be the best strategy to avoid multiple drug failure.
Sequencing nucleoside reverse transcriptase inhibitors
Resistance to NRTIs seems to occur mainly by two mechanisms. First, through the loss of affinity of the RT for the nucleoside analogue, as occurs as a consequence of the selection of the 74V or 184V mutations. Second, resistance can arise as a result of post-replicative repair by pyrophosphorylysis of the analogue chainterminated viral DNA. This seems to be the primary mechanism of resistance to zidovudine. In fact, the pattern of acquisition of mutations over time (codon 70, 215, 41, 219) follows the optimal accomodation of both zidovudine triphosphate discrimination and increased pyrophosphorylysis (42). Failure to zidovudine is usually associated with the appearance of variants bearing these substitutions (43-44), that confer resistance to this drug in most cases (43). Failure to didanosine and/ or stavudine may also be associated with the selection of mutations classically related to resistance to zidovudine, but in only 15-40% of instances (44-46). Isolates with zidovudine-related substitutions seldom show decreased susceptibility to stavudine (44-47), unless the number of these mutations is equal or greater than four (48). Thus, zidovudine may compromise the efficacy of stavudine and stavudine may impair the efficacy ofzidovudine. Zidovudine is associated with higher risk of resistance at the time of failure, but it is unusual that the selected mutant is resistant also to stavudine. Mutations related to resistance to zidovudine are seldom selected by stavudine, but if this occurs, the likelihood of resistance to zidovudine is very high. At the moment, insufficient data are available to establish which one of these two drugs should be used first.
Failure to lamivudine or didanosine tends to be associated with mutations that minimally affect the response to subsequent NRTls. Therefore, each of these two drugs might be a good choice as the first NRTI (42). Variants carrying less than three RT mutations usually retain susceptibility to abacavir (49) , whereas viral response to regimens including this drug may be impaired in the presence of variants bearing more than threeRTsubstitutions (50) . A virus with five previously unidentified mutations (62V + 751 + 77L + I 16Y + 15 I M) that was resistant to zidovudine, didanosine, zalcitabine and stavudine, and partially to lamivudine, has been isolated from patients receiving zidovudine plus didanosine (5 I) or didanosine plus stavudine (45-46). T69XX inserts also reduce susceptibility to all available NRTls (52) .
Isolates resistant to zidovudine and lamivudine retain susceptibility to tenofovir, a nucleotide analogue. Thus, this drug could hopefully be effective in patients who failed multiple NRTls. Furthermore, tenofovir selects only for the 65R mutation, theoretically allowing salvage with other nucleoside analogues (53) .
Sequencing non-nucleoside reverse transcriptase inhibitors
Most of the NNRTI-related mutations reduce NNRTI-binding affinity to the RT, either directly (e.g. the 103N substitution) or indirectly (e.g. the 181C substitution).
In the presence of the 103N mutation the activity of any of the currently available NNRTls is compromised, and this substitution is almost always selected when failure to efavirenz occurs (54) . In the absence of zidovudine, the majority of individuals experiencing early failure to nevi rapine harbor variants bearing the 181C mutation and retaining at least intermediate susceptibility to efavirenz (55) . However, most data suggest that response to efavirenz in individuals who previously failed nevirapine and harbor NNRTI mutants is transient, even in the absence of the 103N substitution (56) (57) (58) . Thus, it seems reasonable to assume that patients have only one chance to achieve durable viral suppression with NNRTls (33) .
Sequencing protease inhibitors
Resistance to PIs arises through the selection of primary and secondary mutations. Primary substitutions are usually (but not always) selected first and may have a discernible effect on drug susceptibility, reducing the binding to the target enzyme. Secondary mutations usually arise on the background of primary mutations; they usually do not affect the binding of the drug to protease and may be selected just because they may compensate for the loss of viral fitness induced by primary substitutions. Also, they heavily contribute to crossresistance among PIs (18) .
Early virological failure to regimens including indinavir, lopinavir and ritonavir or nelfinavir is rarely, if never, associated with the selection of resistance to PIs (24, 59-60). Theoretically, switching to another PI in this setting should guarantee efficacy of the salvage regimen. On the other hand, after more than one failure to a PIincluding regimen, the likelihood of broad crossresistance within this class of drugs is very high (61) (62) .
Virological failure on nelfinavir is associated with the selection of the 30N mutation in twothirds of patients, which reduces susceptibility to the drug without compromising the activity of other PIs, which can effectively be used as a part of rescue regimens (63) . However, approximately one third of individuals who fail on nelfinavir as first PI harbor mutants carrying the 90M mutation, which causes broad PI cross-resistance, thus precluding the use of this class as part of salvage interventions (61, (64) (65) . Thus, drug resistance testing in persons failing a nelfinavir-including regimen may allow the design of a more appropriate rescue combination.
Failure to saquinavir is also frequently accompanied by the emergence of codon 10 and of the 90M mutations (61) . Moreover, response to saquinavir and indinavir may be impaired by the presence of codon 10 mutants (19) , frequently selected by treatment with any of the currently available PI (61) .
Cross-resistance between indinavir and ritonavir is the rule rather than the exception (66) . Therefore, sequencing indinavir with ritonavir, and vice versa, should be avoided. However, boosting indinavir with ritonavir may allow overcoming low to moderate levels of resistance (67) , and failure to indinavir or ritonavir may be rescued by the association of lopinavir with a "baby" dose of ritonavir and efavirenz (40).
Combination regimens including amprenavir may select for four genotypic patterns in patients with virologic rebound: 1) 50V plus other substitutions; 2) 54L/M plus other substitutions; 3) 84V; 4) 321 and 47V (68) . Cross-resistance may thus be lower compared with other PIs (69, 70) , allowing rescue by switching to another PIincluding regimen (71) .
Lopinavir is co-formulated with a "baby" dose of ritonavir (LPVIr) to reach optimal plasma levels and has a high genetic barrier (72) . No PI mutation has been observed in early failure to a LPV/r based HAART when this drug has been used as the first PI (60); theoreticalIy these fai lures could be rescued by any other PI including combination. Furthermore, a salvage regimen of LPV Ir plus efavirenz plus a NRTI has been shown to be highly effective in PI-experienced, NNRTInaive patients failing a PI including HAART (40).
THE ROLE OF RESISTANCE TESTING
As outlined, resistance to many antiretroviral drugs, including most of the NRTIs and all PIs, is not easily predictable simply on the basis of clinical history. Resistance testing is now recommended when changing a failing regimen (25) . This recommendation is based mainly on the results of prospective studies that demonstrated an advantage of genotypic (20) (21) or phenotypic tests over clinical history (22) . In particular, the CPCRA 046 study showed how, also in drug experienced persons, at least three active drugs have to be introduced in the new regimen to obtain a greater than 1 log., reduction of pVL at 12 weeks, and how this result is more likely achieved if resistance testing is employed (21) . At the moment, there is insufficient data to establish the superiority of one test over the other. Genotype is cheaper, less technically demanding, requires less turn-around times, and a correlation between specific mutations and virological outcome is well established. However, it is not a measure of drug susceptibility. Moreover, resistance to stavudine, zalcitabine, didanosine and abacavir may be hardly predictable on the basis of genotype. This may be true also for PIs, especially after more than one failure (62) . Phenotype provides a direct measure of drug susceptibility and more familiar results (IC so ) ' However, resistance cut-offs predictive of virological failure are not yet well established.
Nevertheless, phenotype provides an indispensable information to determine drug inhibitory quotients (IQ) and may be useful to assess resistance to stavudine, didanosine, zalcitabine, abacavir and PIs. Virtual phenotype is one of the algorithms developed to overcome difficulties in the interpretation of genotyping, avoiding costs of phenotyping. It might be superior to other standardized rule based interpretations in predicting virological outcome (73) (74) ; however, these findings need to be confirmed in prospective studies.
PHARMACOKINETIC ENHANCEMENT
Resistance is a continuum rather than a discrete threshold phenomenon, in which increasing degrees of reduced susceptibility are developed over time. Ritonavir is a potent inhibitor of the CYP3A4 enzyme of the cytochrome P450 complex; moreover, it inhibits the gut-cell wall p-glycoprotein, responsible for PI cell efflux. All PIs are substrates of both P450 complex and p-glycoprotein. Therefore, the co-administration ("boosting") of one PI with ritonavir let the "boosted" PI to reach plasma concentrations of greater than up to 70fold the wild-type IC 50 or IC 95 , thus allowing the overcoming of mild to moderate degrees of resistance (67) .
Results ofLPVIrin drug-experienced persons seem to confirm the efficacy of this strategy (40). Furthermore, in these patients IQ (Clrnug/ECso) values of greater than 15 proved to be predictive of efficacy, whereas C. h levels alone did not roug (75) .
STRUCTURED TREATMENT INTERRUP-TIONS
Cross-resistance among antiretroviral drugs Iimits the chances of success of salvage regimens. One retrospective (76) and two short-term prospective studies (77) (78) have shown that treatment interruptions in this setting allow the wild-type viral population in plasma to become predominant, by overgrowing resistant variants. The likelihood of this "reversion" to wild-type was higher among individuals with higher baseline CD4+ cell counts. However, when wild-type virus becomes predominant in plasma, an abrupt fall in CD4+ cells is frequently observed, thus exposing patients to the risk of developing opportunistic pathologies. Furthermore, despite the loss of detectable resistance in plasma, a resistant virus was still cultured from peripheral-blood mononuclear cells in the majority of subjects. Nonetheless, reintroduction of therapy was associated with a rapid decline ofpVL and with an increase in CD4+ cell count in the short-term period when shift to wild-type occurred. Therefore, long-term prospective studies are needed to establish whether this strategy could ultimately yield a clinical benefit, at least in patients with high baseline CD4+ cell counts.
CONCLUSIONS
The management of failure to antiretroviral drugs is a complex and challenging issue. The optimal time point to change a virologically failing regimen is not yet clearly defined. When deciding to modify a regimen the number of previous failures, together with both the virological and the immunological response, should be taken into account. Best results are obtained when at least three active drugs are introduced in the new regimen. This goal is more likely achieved when the choice is driven by the result of a resistance test. If a PI is considered for the salvage regimen, boosting with ritonavir may improve efficacy, allowing mild to moderate resistance to be overcome. Treatment interruptions in the setting of broad resistance to antiretrovirals need to be further investigated. 
